EIKN - Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung
EIKN - Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Story updates
11:37:09 AM UTC
SquawkNews
EIKN eikon Therapeutics announces first patient dosed in teluride-008, a registrational phase 2/3 trial of eik1001 in non-small cell lung cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.